Combination of Angiotensin II Receptor Antagonist with Calcium Channel Blocker or Diuretic as Antihypertensive Therapy for Patients with Chronic Kidney Disease

REFERENCES

• Mancia G, De Backer G, Dominiczak A, Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462–1536.
   PubMed Web of Science ®Google Scholar
• Ishimitsu T. Points at issue in the Japanese Society of Hypertension's Guidelines for the Management of Hypertension (JSH2009). Jpn J Nephrol 2009;51:456–460.
   Google Scholar
• Ando Y, Ito S, Uemura O, CKD Clinical Practice Guidebook. The essence of treatment for CKD patients. Clin Exp Nephrol 2009;13:191–248.
   PubMedGoogle Scholar
• Hasebe N, Kikuchi K. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: The NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005;23: 445–453.
   PubMed Web of Science ®Google Scholar
• Saito I, Saruta T. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study. Hypertens Res 2006;29:789–796.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008;73:1303–1309.
   PubMed Web of Science ®Google Scholar
• Buchner N, Banas B, Kramer BK. Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med 2008;359:426.
   PubMed Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M, Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982–992.
   PubMed Web of Science ®Google Scholar
• Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb 2006;13: 101–107.
   PubMed Web of Science ®Google Scholar
• Takaki A, Ogawa H, Wakeyama T, Cardio-ankle vascular index is superior to brachial-ankle pulse wave velocity as an index of arterial stiffness. Hypertens Res 2008;31:1347–1355.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Williams M, Dworkin L, Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646–661.
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305.
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547–553.
   PubMed Web of Science ®Google Scholar
• Brown MJ, Palmer CR, Castaigne A, Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366–372.
   PubMed Web of Science ®Google Scholar
• de Leeuw PW, Ruilope LM, Palmer CR, Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004;164:2459–2464.
   PubMed Web of Science ®Google Scholar
• Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990;335: 1109–1113.
   PubMed Web of Science ®Google Scholar
• Mancini GB, Miller ME, Evans GW, Byington R, Furberg CD, Pitt B. Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT). Am J Cardiol 2002;89: 1414–1416.
   PubMed Web of Science ®Google Scholar
• Shinoda E, Yui Y, Kodama K, Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study). Hypertension 2005;45:1153–1158.
   PubMed Web of Science ®Google Scholar
• MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J 1985;291:97–104.
   PubMed Web of Science ®Google Scholar
• Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. Br Med J 1990;300:975–978.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Ishizuka N, Miyashita H, Shirai K. CAVI; Toward the standarization of non-invasive blood pressure independent arterial wall stiffness parameter -epidemiological study. Electronics Clinical Science 2008;76:35–45.
   Google Scholar
• Kita T, Tokashiki M, Kitamura k. Long-term therapy with nifedipine-CR improves arterio-sclerosis retated markers in patients with untreated essential hypertension. The Open Hypertension Journal 2008;1:1–6.
   Google Scholar
• Asmar R. Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: clinical implications. Am J Cardiovasc Drugs 2001;1:387–397.
   PubMedGoogle Scholar
• Hamada T, Hisatome I, Kinugasa Y, Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002;41:793–797.
   PubMed Web of Science ®Google Scholar
• Yokoyama S, Mori N, Takayama S, Hosino T, Kaburagi T. Renal effects of nifedipine, a calcium antagonist, administered as anti-hypertensive drug. Jpn J Nephrol 1985; 27:1451–1457.
   Google Scholar
• Pevahouse JB, Markandu ND, Cappuccio FP, Buckley MG, Sagnella GA, MacGregor GA. Long term reduction in sodium balance: possible additional mechanism whereby nifedipine lowers blood pressure. Br Med J 1990; 301:580–584.
   PubMed Web of Science ®Google Scholar
• Hamada T, Hisatome I, Sugihara S. Effect of nifedipine coat-core for the prevention of myofibril hyperuricemia in essential hypertensive patient. Prog Med 2004;24: 1285–1288.
   Google Scholar
• Ishimitsu T, Numabe A, Masuda T, Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 2009;32:962–968.
   PubMed Web of Science ®Google Scholar
• Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998;13:1682–1685.
   PubMed Web of Science ®Google Scholar